Hospital Pharmacy - July/August 2018 - 264

264
known drug allergies. He denied tobacco, alcohol, or illicit
drug use. Notably, he worked as a taxidermist at a farm.
Upon initial examination, he noted having several tick bites
a few weeks ago while working at his job, after which he
developed erythema migrans on his right arm and abdomen.
He denied any recent travel history.
Physical examination revealed a heart rate of 40 beats per
minute, blood pressure of 134/74 mmHg, respiratory rate of
20 breaths per minute, and temperature of 98.6 degree
Fahrenheit. The review of systems was remarkable for an erythematous macular rash with central clearing on the anterior
aspect of right arm. Laboratory tests, including troponin I (reference <0.04 ng/mL), were unremarkable. An initial electrocardiogram (ECG) revealed a second-degree AV block,
fluctuating between Mobitz type I and Mobitz type II heart
block, with a P-R interval of 300 ms. The patient was transferred to cardiovascular intensive care unit (CVICU) for closer
monitoring. Enzyme-linked immunosorbent assay (ELISA)
and Western immunoblot tests were performed and sent to the
laboratory for analysis. A presumptive diagnosis of Lyme carditis was established based on the confirmed history of tick
exposure, presence of erythema migrans, and AV block. The
patient was started on ceftriaxone 2 g every 24 hours. In addition, heparin 5000 units/mL subcutaneous injection every 12
hours was initiated for venous thromboembolism prevention.
All of the patient's home medications, except carvedilol and
lisinopril, were restarted. Carvedilol, a nonselective β-blocker
and α1 blocker, was held to prevent the patient's heart rate
from dropping further and worsening his bradycardia. Cardiac
Electrophysiology Service was consulted and agreed with the
primary team's plan for conservative management and did not
see a need for a pacemaker placement.
On day 3 of hospitalization, patient's heart rate was found
to be between 50 and 60 beats per minute. The diagnosis of
Lyme disease was confirmed based on the presence of
Borrelia antibodies demonstrated by ELISA and Western
immunoblot findings (positive for IgG and IgM anti-Borrelia
antibodies). A transthoracic echocardiogram revealed an
ejection fraction of 60% to 65%, normal right ventricular
systolic function, and no significant valve disease. A repeat
ECG revealed a first-degree AV block with a P-R interval of
300 ms. When compared with the initial ECG, the patient
was no longer in second-degree AV block. As the patient's
second-degree heart block had resolved, he was transferred
from the CVICU to the general medicine floor, where he
continued to receive ceftriaxone 2 g every 24 hours.
On day 5 of hospitalization, there was a marked improvement in the patient's clinical status; though, he continued to
experience weakness and fatigue. After the placement of a
peripherally inserted central catheter line, the patient was
discharged to his home on a 28-day course of ceftriaxone 2 g
every 24 hours. On the day of discharge, the patient's vitals
were as follows: heart rate of 65 beats per minute, blood
pressure of 138/74 mmHg, respiratory rate of 20 breaths per
minute, and temperature of 98 degree Fahrenheit. The patient

Hospital Pharmacy 53(4)
did not develop any neurologic symptoms of Lyme disease
over the course of his hospital stay. Upon discharge, all of
patient's home medications, including carvedilol and lisinopril, were restarted. In addition, the patient was instructed to
follow-up with his primary care physician and cardiologist
on an outpatient basis.

Discussion
Lyme carditis is an uncommon manifestation of Lyme disease, occurring in approximately 4% to 8% of patients with
untreated Lyme disease.3 Lyme carditis results from direct
invasion of cardiac tissues by spirochetes, and can involve
all layers of the heart.4,5 Patients with Lyme carditis most
commonly present with some degree of AV conduction
blockade, which can fluctuate rapidly and progress from
a first-degree block to a His-Purkinje block within a few
minutes.6 A review of 105-patient case reports of patients
with Lyme carditis revealed that 49% of patients experienced
third-degree AV block, 16% of patients experienced seconddegree AV block, and 12% of patients experienced firstdegree AV block.7 The highest risk of progression to complete
AV block was noted to be in patients with a P-R interval of
≥300 ms.7 Even though the most common manifestation of
Lyme carditis is AV block, patients can also present with
endocarditis, myocarditis, pancarditis, pericarditis, and QTc
interval prolongation.4 Notably, 3 cases of sudden cardiac
death due to Lyme carditis have been reported to date.8 While
patients with Lyme carditis can be completely asymptomatic,
patients with a high-degree AV block usually present with
symptoms such as chest pain, palpitations, shortness of
breath, light-headedness, and/or syncope or near-syncope.3
The degree of severity of some of these symptoms typically
increases as the degree of heart block progresses.

Diagnosis
There are no standardized diagnostic criteria for Lyme carditis. Diagnosis of Lyme carditis is established primarily by
clinical and epidemiological findings. Serologic testing,
through detection of antibodies to Borrelia burgdorferi, is
used to support the clinical diagnosis.6 When performing
serologic testing, a 2-tiered approach is recommended in
which a positive or equivocal ELISA is followed by a confirmatory Western immunoblot test.8 However, as the majority
of patients with established late stage Lyme disease infection
are seropositive, seropositivity alone is not sufficient to confirm a diagnosis of Lyme carditis.6 It is imperative that serological testing be interpreted in the light of clinical
presentation and possible exposure to establish a diagnosis.6

Management
Patients who are experiencing (1) syncope, dyspnea, or chest
pain; (2) a second- or third-degree AV block; or (3) a



Table of Contents for the Digital Edition of Hospital Pharmacy - July/August 2018

Ed Board
TOC
Antibiotic Stewardship: The Health of the World Depends on It
ISMP Medication Error Report Analysis: CycloSPORINE Dispensing Errors
ISMP Adverse Drug Reactions
Summaries of Safety Labeling Changes Approved By FDA: Boxed Warnings Highlights January-March 2018
Restructuring a Pharmacy Department: Leadership Strategies for Managing Organizational Change
Angiotensin II
RxLegal: A Rapid Review of Right-To-Try
New Medications in the Treatment of Hereditary Transthyretin Amyloidosis
Significant Published Articles for Pharmacy Nutrition Support Practice in 2017
Utilization of Lean Techniques in Pharmacy Residency Training: Modifying the PGY1 Management and Leadership Experience
Impact of a Clinical Decision Support Tool on Cancer Pain Management in Opioid-Tolerant Inpatients
Lyme Carditis: A Case Report and Review of Management
Impact of the Implementation of Project Re-Engineered Discharge for Heart Failure patients at a Veterans Affairs Hospital at the Central Arkansas Veterans Healthcare System
Evaluation of Oritavancin Use at a Community Hospital
Hospital Pharmacy - July/August 2018 - Cover1
Hospital Pharmacy - July/August 2018 - Cover2
Hospital Pharmacy - July/August 2018 - 201
Hospital Pharmacy - July/August 2018 - 202
Hospital Pharmacy - July/August 2018 - 203
Hospital Pharmacy - July/August 2018 - 204
Hospital Pharmacy - July/August 2018 - 205
Hospital Pharmacy - July/August 2018 - Ed Board
Hospital Pharmacy - July/August 2018 - 207
Hospital Pharmacy - July/August 2018 - TOC
Hospital Pharmacy - July/August 2018 - 209
Hospital Pharmacy - July/August 2018 - 210
Hospital Pharmacy - July/August 2018 - 211
Hospital Pharmacy - July/August 2018 - 212
Hospital Pharmacy - July/August 2018 - 213
Hospital Pharmacy - July/August 2018 - Antibiotic Stewardship: The Health of the World Depends on It
Hospital Pharmacy - July/August 2018 - 215
Hospital Pharmacy - July/August 2018 - 216
Hospital Pharmacy - July/August 2018 - ISMP Medication Error Report Analysis: CycloSPORINE Dispensing Errors
Hospital Pharmacy - July/August 2018 - 218
Hospital Pharmacy - July/August 2018 - 219
Hospital Pharmacy - July/August 2018 - ISMP Adverse Drug Reactions
Hospital Pharmacy - July/August 2018 - 221
Hospital Pharmacy - July/August 2018 - 222
Hospital Pharmacy - July/August 2018 - Summaries of Safety Labeling Changes Approved By FDA: Boxed Warnings Highlights January-March 2018
Hospital Pharmacy - July/August 2018 - 224
Hospital Pharmacy - July/August 2018 - Restructuring a Pharmacy Department: Leadership Strategies for Managing Organizational Change
Hospital Pharmacy - July/August 2018 - 226
Hospital Pharmacy - July/August 2018 - 227
Hospital Pharmacy - July/August 2018 - 228
Hospital Pharmacy - July/August 2018 - 229
Hospital Pharmacy - July/August 2018 - Angiotensin II
Hospital Pharmacy - July/August 2018 - 231
Hospital Pharmacy - July/August 2018 - 232
Hospital Pharmacy - July/August 2018 - 233
Hospital Pharmacy - July/August 2018 - RxLegal: A Rapid Review of Right-To-Try
Hospital Pharmacy - July/August 2018 - 235
Hospital Pharmacy - July/August 2018 - New Medications in the Treatment of Hereditary Transthyretin Amyloidosis
Hospital Pharmacy - July/August 2018 - 237
Hospital Pharmacy - July/August 2018 - 238
Hospital Pharmacy - July/August 2018 - Significant Published Articles for Pharmacy Nutrition Support Practice in 2017
Hospital Pharmacy - July/August 2018 - 240
Hospital Pharmacy - July/August 2018 - 241
Hospital Pharmacy - July/August 2018 - 242
Hospital Pharmacy - July/August 2018 - 243
Hospital Pharmacy - July/August 2018 - 244
Hospital Pharmacy - July/August 2018 - 245
Hospital Pharmacy - July/August 2018 - 246
Hospital Pharmacy - July/August 2018 - Utilization of Lean Techniques in Pharmacy Residency Training: Modifying the PGY1 Management and Leadership Experience
Hospital Pharmacy - July/August 2018 - 248
Hospital Pharmacy - July/August 2018 - 249
Hospital Pharmacy - July/August 2018 - 250
Hospital Pharmacy - July/August 2018 - 251
Hospital Pharmacy - July/August 2018 - 252
Hospital Pharmacy - July/August 2018 - 253
Hospital Pharmacy - July/August 2018 - 254
Hospital Pharmacy - July/August 2018 - 255
Hospital Pharmacy - July/August 2018 - Impact of a Clinical Decision Support Tool on Cancer Pain Management in Opioid-Tolerant Inpatients
Hospital Pharmacy - July/August 2018 - 257
Hospital Pharmacy - July/August 2018 - 258
Hospital Pharmacy - July/August 2018 - 259
Hospital Pharmacy - July/August 2018 - 260
Hospital Pharmacy - July/August 2018 - 261
Hospital Pharmacy - July/August 2018 - 262
Hospital Pharmacy - July/August 2018 - Lyme Carditis: A Case Report and Review of Management
Hospital Pharmacy - July/August 2018 - 264
Hospital Pharmacy - July/August 2018 - 265
Hospital Pharmacy - July/August 2018 - Impact of the Implementation of Project Re-Engineered Discharge for Heart Failure patients at a Veterans Affairs Hospital at the Central Arkansas Veterans Healthcare System
Hospital Pharmacy - July/August 2018 - 267
Hospital Pharmacy - July/August 2018 - 268
Hospital Pharmacy - July/August 2018 - 269
Hospital Pharmacy - July/August 2018 - 270
Hospital Pharmacy - July/August 2018 - 271
Hospital Pharmacy - July/August 2018 - Evaluation of Oritavancin Use at a Community Hospital
Hospital Pharmacy - July/August 2018 - 273
Hospital Pharmacy - July/August 2018 - 274
Hospital Pharmacy - July/August 2018 - 275
Hospital Pharmacy - July/August 2018 - 276
Hospital Pharmacy - July/August 2018 - Cover3
Hospital Pharmacy - July/August 2018 - Cover4
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2020
https://www.nxtbook.com/nxtbooks/sage/psychologicalscience_demo
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2020
https://www.nxtbook.com/nxtbooks/sage/fai_202009
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_august2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2019
https://www.nxtbook.com/nxtbooks/sage/fai_201909
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_july2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2019
https://www.nxtbook.com/nxtbooks/sage/canadianpharmacistsjournal_05062019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2019
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201903
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2018
https://www.nxtbook.com/nxtbooks/sage/tec_20180810
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2018
https://www.nxtbook.com/nxtbooks/sage/fai_201807
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2018
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201803
https://www.nxtbook.com/nxtbooks/sage/slas_discovery_201712
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_november2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_september2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2017
https://www.nxtbook.com/nxtbooks/sage/fai_supplement_201709
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_may2017
https://www.nxtbook.com/nxtbooks/sage/fai_201706
https://www.nxtbook.com/nxtbooks/sage/fai_201607
https://www.nxtbookmedia.com